echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The patient monitor was approved for marketing

    The patient monitor was approved for marketing

    • Last Update: 2023-02-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the State Medical Products Administration approved the registration application
    for the innovative product "patient monitor" produced by Shenzhen Keman Medical Equipment Co.
    , Ltd.
    after review.
     
    The product consists of
    a host, plug-in modules, and accessories.
    It can monitor patients with ECG (including ST-segment measurement and arrhythmia analysis), impedance respiration, body temperature, pulse oximetry, pulse rate, non-invasive blood pressure, invasive blood pressure, respiratory and end-respiratory carbon dioxide, anesthetic gas, non-invasive cardiac output (only for adult patients), invasive cardiac output (only for adult patients), and has the functions
    of electrocardiogram, PICC, respiratory oxygenation, renal function calculation, hemodynamic calculation, oxygenation calculation, ventilation calculation, drug calculation, and recorder 。 The product is intended to be used by trained and qualified professional clinicians and nurses in healthcare facilities in applications such as operating rooms, ICUs and general departments
    .
     
    The product adopts ECG signal adaptive filtering technology and four-electrode ECG system technology, which can realize the real-time positioning
    of the catheter end during catheter insertion operation by observing the change of cavity electrocardiogram P wave in real time and feedback the position of the catheter end.
    Compared with traditional central venous catheterization methods, this product has the function of central venous catheterization end positioning, which helps to improve the PICC catheter placement rate
    .
     
    The drug administration department will strengthen the post-marketing supervision of the product to protect the safety of
    patients.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.